Lymphoblastic Leukemia

Oncology
4
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Kura Oncology
Kura OncologySAN DIEGO, CA
1 program
1
DexamethasonePhase 1/21 trial
Active Trials
NCT05848687Recruiting90Est. Dec 2033
United Therapeutics
United TherapeuticsMD - Silver Spring
1 program
1
DexamethasonePhase 1/2
GS
Gilead SciencesFOSTER CITY, CA
2 programs
2
DasatinibPhase 1Small Molecule1 trial
DasatinibPhase 1Small Molecule
Active Trials
NCT05993949Active Not Recruiting8Est. Jun 2027

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
2029
2030
2031
Kura OncologyDexamethasone
Gilead SciencesDasatinib

Clinical Trials (2)

Total enrollment: 98 patients across 2 trials

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Start: Nov 2023Est. completion: Dec 203390 patients
Phase 1/2Recruiting

Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

Start: Oct 2023Est. completion: Jun 20278 patients
Phase 1Active Not Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 98 patients
Small Molecule is the dominant modality (100% of programs)
3 companies competing in this space